Future Aspects of Somatostatin- Receptor-Mediated Therapy

Publisher： Karger

E-ISSN： 1423-0194|80|1|57-61

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.80, Iss.1, 2004-10, pp. : 57-61

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of Glucocorticoids in the Regulation of Pituitary Somatostatin Receptor Subtype (sst1–sst5) mRNA Levels: Evidence for Direct and Somatostatin-Mediated Effects

By  

Neuroendocrinology, Vol. 78, Iss. 3, 2003-10 ,pp. : 163-175

Karger

Access to resources Recommend Favorite

Aberrant Receptor-Mediated Cushing’s Syndrome

By  

Hormone Research in Paediatrics, Vol. 59, Iss. 1, 2004-11 ,pp. : 99-103

Karger

Access to resources Recommend Favorite

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

By  

Neuroendocrinology, Vol. 90, Iss. 2, 2009-08 ,pp. : 220-226

Karger

Access to resources Recommend Favorite

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

By  

Neuroendocrinology, Vol. 105, Iss. 3, 2017-04 ,pp. : 295-309

Karger

Access to resources Recommend Favorite

Radionuclide Therapy via SSTR: Future Aspects from Experimental Animal Studies

By  

Neuroendocrinology, Vol. 97, Iss. 1, 2012-05 ,pp. : 86-98

Karger

Access to resources Recommend Favorite